Search results

...ffective than GLP-1 mono agonists although there have been no head to head trials as of 2023. ...ced by glucagon receptor activation. Several such drugs have reached human trials for obesity, diabetes, and non-alcoholic fatty liver disease but adverse ef ...

...ffective than GLP-1 mono agonists although there have been no head to head trials as of 2023. ...ced by glucagon receptor activation. Several such drugs have reached human trials for obesity, diabetes, and non-alcoholic fatty liver disease but adverse ef ...

<!--Clinical data--> Adverse effects found in clinical trials are usually limited to headache and gastrointestinal discomfort when high d ...

<!-- Clinical data --> ==Clinical trials== ...

<!--Clinical data--> Adverse effects found in clinical trials are usually limited to headache and gastrointestinal discomfort when high d ...

<!-- Clinical data --> ==Clinical trials== <!--T:8--> ...

<!--Clinical data--> ...g]] to treat diabetic polyneuropathy. A 2021 review described two clinical trials with positive results for diabetic polyneuropathy and concluded that more r ...

<!-- Clinical data --> {{Anchor|Clinical trials}} ...

<!--Clinical data--> ...g]] to treat diabetic polyneuropathy. A 2021 review described two clinical trials with positive results for diabetic polyneuropathy and concluded that more r ...

==Pipeline and clinical trials== 2013年12月時点で、Amgenは11の医薬品を第III相[[clinical trials/ja|臨床試験]]中である。 ...

...ides decreased by 19%, and HDL cholesterol was increased by 9% in clinical trials with daily intakes ranging from 600 to 1200&nbsp;mg/day. ...

<!--Clinical data--> ...[[DMARD|disease modifying drug]], on the basis of the results of clinical trials. In many countries it is available over the counter and is widely advertise ...

...ides decreased by 19%, and HDL cholesterol was increased by 9% in clinical trials with daily intakes ranging from 600 to 1200&nbsp;mg/day. ...

<!--Clinical data--> ...[[DMARD|disease modifying drug]], on the basis of the results of clinical trials. In many countries it is available over the counter and is widely advertise ...

...ing in the laboratory to clinical trial development, including Phase I–III trials – to approved vaccine or drug typically takes more than a decade.<ref name= Broadly, the process of drug development can be divided into preclinical and clinical work. ...

...漿中の正常なグルコース濃度も低血糖を起こすことなく上昇させるようであった。残念なことに、これらの特性にもかかわらず、フロリジンはいくつかの理由から[[clinical development/ja|臨床開発]]には十分適していなかった。フロリジンは[[gastrointestinal tract/ja|消化管]]で分 フロリジンはそれ以上の[[clinical trials/ja|臨床試験]]には適さなかったが、SGLT-2阻害薬の開発において重要な役割を果たした。それは、安全性と忍容性のプロファイルが改善されたSGLT阻 ...